Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
BPC-157 is a peptide therapy gaining attention for its ability to support muscle growth and recovery
Not approved for human use
As a small, defined peptide it is straightforward to synthesize and verify see what is a peptide and what is an amino acid
The standard research protocol is 300 mcg per day, subcutaneous, administered in a fasted state, typically in the morning before food or exercise
Unlike pharmaceutical sleep aids that cause next-day drowsiness, cognitive impairment, tolerance, and dependency, DSIP enhances sleep quality without sedative side effects, maintains normal sleep architecture, causes no morning grogginess, develops no tolerance requiring dose escalation, and demonstrates no withdrawal symptoms or addiction potential